Here are relevant reports on : microbiome-therapeutics-market
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
The global microbiome diagnostics market, valued at US$126 million in 2022, stood at US$146 million in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$300 million by the end of the period. Market growth is driven by the rising incidence of chronic diseases, collaborative efforts between microbiome industry and academic institutes, and growing demand of personalized medicine.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Microbiome Sequencing Services Market by Service (Sample Preparation, Sequencing, Library Preparation), Type (Amplicon Sequencing, Whole Genome Sequencing), Technology (Sequencing by Synthesis, Nanopore Sequencing), End User - Global Forecast to 2028
The global microbiome sequencing services market, valued at US$250 million in 2022, stood at US$284 million in 2023 and is projected to advance at a resilient CAGR of 14.3% from 2023 to 2028, culminating in a forecasted valuation of US$555 billion by the end of the period. Growth in this market is primarily driven by the increasing demand for metagenomic sequencing, the growing focus on the development of human microbiome therapeutics, and the high cost of advanced sequencing infrastructure.
- Published: May 2023
- Price: $ 4950
- TOC Available:
-
Rotator Cuff Injury Treatment Market by Modality (Surgical (Arthroscopy, Shoulder Replacement, Tendon Repair), Physiotherapy (Braces, Cold Compression), Drug Therapeutics (Anti-inflammatory Drugs, Injections), Orthobiologics) - Global Forecast to 2026
The global rotator cuff injury treatment market growth is primed to transition from $989.3 million in 2021 to $1,244.2 million by 2026, showcasing a strong CAGR of 4.7%. The key factors fueling the growth of this market include an increase in sports-related shoulder injuries, technological advancements in arthroscopic surgical devices, increase in aging population with osteoarthritis, strong focus of players towards launch of highly advanced arthroscopic treatment devices.
- Published: April 2022
- Price: $ 4950
- TOC Available:
-
US Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User [Hospital, Home Healthcare] Forecast to 2031
The US Medical Gas and Equipment Market, valued at USD 8.18 million in 2024, stood at USD 8.63 million in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2031, culminating in a forecasted valuation of USD 11.97 million by the end of the period. The growth of the medical gas and equipment market in US is primarily driven by the rising incidence of respiratory and chronic diseases, including COPD, asthma, cardiovascular disorders, and sleep apnea, as well as a rapidly aging population that requires long-term oxygen therapy and critical care support.
- Published: April 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
